Emergent Biosolutions, Inc. (EBS): Price and Financial Metrics
EBS Price/Volume Stats
| Current price | $2.28 | 52-week high | $10.88 |
| Prev. close | $2.16 | 52-week low | $1.42 |
| Day low | $2.13 | Volume | 750,564 |
| Day high | $2.36 | Avg. volume | 2,670,782 |
| 50-day MA | $2.41 | Dividend yield | N/A |
| 200-day MA | $3.21 | Market Cap | 119.45M |
EBS Stock Price Chart Interactive Chart >
Emergent Biosolutions, Inc. (EBS) Company Bio
Emergent BioSolutions is a biopharmaceutical company which develops, manufactures, and delivers a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. The company was founded in 1998 and is based in Gaithersburg, Maryland.
Latest EBS News From Around the Web
Below are the latest news stories about EMERGENT BIOSOLUTIONS INC that investors may wish to consider to help them evaluate EBS as an investment opportunity.
Why Is Icosavax (ICVX) Stock Up 46% Today?Icosavax stock is up on Tuesday as investors react to an acquisition deal with AstraZeneca that values ICVX between $15 and $20 per share. |
EBS Stock Earnings: Emergent BioSolutions Misses EPS, Beats Revenue for Q3 2023EBS stock results show that Emergent BioSolutions missed analyst estimates for earnings per share but beat on revenue for the third quarter of 2023. |
Emergent Biosolutions (EBS) Reports Q3 Loss, Tops Revenue EstimatesEmergent Biosolutions (EBS) delivered earnings and revenue surprises of -1,100% and 5.94%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock? |
Emergent (EBS) Gets $75M BARDA Contract for Anthrax VaccineThe BARDA is exercising an option to procure additional doses of Emergent BioSolutions' (EBS) recently approved anthrax vaccine. Deliveries will likely be completed by the end of first-quarter 2024. |
Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted)GAITHERSBURG, Md., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the Biomedical Advanced Research and Development Authority (BARDA) within the Administration for Strategic Preparedness and Response at the United States Department of Health and Human Services has awarded a $75 million option to Emergent’s existing contract (HHSO100201600030C) for the acquisition of newly licensed anthrax vaccine CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted). Deli |
EBS Price Returns
| 1-mo | -5.39% |
| 3-mo | 21.28% |
| 6-mo | 6.05% |
| 1-year | -77.51% |
| 3-year | -96.32% |
| 5-year | -95.77% |
| YTD | -5.00% |
| 2023 | -79.68% |
| 2022 | -72.83% |
| 2021 | -51.48% |
| 2020 | 66.08% |
| 2019 | -8.99% |
Continue Researching EBS
Want to do more research on Emergent BioSolutions Inc's stock and its price? Try the links below:Emergent BioSolutions Inc (EBS) Stock Price | Nasdaq
Emergent BioSolutions Inc (EBS) Stock Quote, History and News - Yahoo Finance
Emergent BioSolutions Inc (EBS) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...